↓ Skip to main content

Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease

Overview of attention for article published in Hematology Journal, January 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

twitter
33 X users

Citations

dimensions_citation
40 Dimensions

Readers on

mendeley
32 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease
Published in
Hematology Journal, January 2018
DOI 10.3324/haematol.2017.183434
Pubmed ID
Authors

William R. Drobyski, Aniko Szabo, Fenlu Zhu, Carolyn Keever-Taylor, Kyle M. Hebert, Renee Dunn, Sharon Yim, Bryon Johnson, Anita D’Souza, Mary Eapen, Timothy S. Fenske, Parameswaran Hari, Mehdi Hamadani, Mary M. Horowitz, J. Douglas Rizzo, Wael Saber, Nirav Shah, Bronwen Shaw, Marcelo Pasquini

Abstract

We conducted a phase 2 study in which patients undergoing allogeneic hematopoietic stem cell transplantation received Tocilizumab in addition to standard immune suppression with tacrolimus and methotrexate for graft versus host disease prophylaxis. Thirty-five patients were enrolled between January 2015 and June 2016. The median age of the cohort was 66 (range 22-76). All patients received busulfan-based conditioning, and were transplanted with HLA-matched related or matched unrelated bone marrow or peripheral stem cell grafts. The median follow up for surviving patients was 15 months (range 9-20). The cumulative incidences of grades II-IV and III-IV acute graft versus host disease were 14% (95% CI 5-30) and 3% (95% CI 0-11) at day 100, and 17% (95% CI 7-31) and 6% (95% CI 1-16) at day 180, respectively. There was no difference in grades II-IV acute graft versus host disease in recipients that received myeloablative or reduced intensity conditioning regimens. Notably, there were no cases of graft versus host disease of the lower gastrointestinal tract within the first 100 days. A comparison to 130 matched controls who only received tacrolimus and methotrexate demonstrated a lower cumulative incidence of grades II-IV acute graft versus host disease (17% versus 45%, p=0.003) and a significant increase in grades II-IV acute graft versus host disease -free survival at 6 months (69% versus 42%, p=0.001) with Tocilizumab, tacrolimus and methotrexate which was the primary endpoint of the study. Immune reconstitution was preserved in patients treated with Tocilizumab, tacrolimus and methotrexate as T and B cell subsets recovered to near normal levels by 6-12 months post transplantation. We conclude that Tocilizumab has promising activity in preventing acute graft versus host disease, particularly in the lower gastrointestinal tract, and warrants further examination in a randomized setting.

X Demographics

X Demographics

The data shown below were collected from the profiles of 33 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 32 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 13%
Student > Bachelor 3 9%
Other 3 9%
Researcher 3 9%
Student > Ph. D. Student 2 6%
Other 6 19%
Unknown 11 34%
Readers by discipline Count As %
Medicine and Dentistry 12 38%
Biochemistry, Genetics and Molecular Biology 1 3%
Business, Management and Accounting 1 3%
Computer Science 1 3%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Other 4 13%
Unknown 12 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 April 2021.
All research outputs
#1,948,825
of 25,382,440 outputs
Outputs from Hematology Journal
#263
of 4,085 outputs
Outputs of similar age
#44,607
of 451,056 outputs
Outputs of similar age from Hematology Journal
#4
of 91 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,085 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,056 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 91 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.